Literature DB >> 6994788

Guanfacine in essential hypertension: effect on blood pressure, plasma noradrenaline concentration and plasma renin activity.

W Schoeppe, H M Brecht.   

Abstract

1. The acute and chronic effects of guanfacine on blood pressure, plasma noradrenaline concentration and plasma renin activity were investigated in 23 patients (15 males, 8 females) with essential hypertension (WHO grade I-II). 2. Guanfacine induced a decrease in plasma noradrenaline concentration and plasma renin activity concomitant with a fall in blood pressure and heart rate in both the acute and the chronic study. 3. The adrenergic response to upright posture, reflected by an increase in plasma noradrenaline concentration and plasma renin activity, was not abolished after chronic guanfacine therapy. 4. The decrease in blood pressure 15 min after intravenous administration of guanfacine was inversely correlated with the basal sympathetic activity before treatment and with the decrease in plasma noradrenaline. 5. After chronic treatment with guanfacine no significant correlation existed between blood pressure reduction and the concomitant changes in peripheral sympathetic and/or plasma renin activity. 6. Despite the lack of a close correlation it is suggested that the antihypertensive effect of guanfacine in patients with essential hypertension is at least partially mediated by an inhibition of the sympathetic nervous and plasma renin activity.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6994788      PMCID: PMC1430128          DOI: 10.1111/j.1365-2125.1980.tb04914.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  10 in total

Review 1.  Pharmacological evidence for a central alpha-sympathomimetic mechanism controlling blood pressure and heart rate.

Authors:  M Laubie; B Delbarre; D Bogaievsky; Y Bogaievsky; D Tsoucaris-Kupfer; D Senon; H Schmitt; H Schmitt
Journal:  Circ Res       Date:  1976-06       Impact factor: 17.367

2.  Decrease in plasma noradrenaline levels following long-term treatment with prindolol in patients with essential hypertension.

Authors:  H M Brecht; F Banthien; W Schoeppe
Journal:  Klin Wochenschr       Date:  1976-11-15

3.  The central hypotensive action of clonidine and BAY 1470 in cats and rats.

Authors:  L Finch
Journal:  Clin Sci Mol Med Suppl       Date:  1975-06

4.  Effects of clonidine and BS 100-141 on the EEG sleep pattern in rats.

Authors:  H Kleinlogel; G Scholtysik; A C Sayers
Journal:  Eur J Pharmacol       Date:  1975-08       Impact factor: 4.432

Review 5.  New trends in pharmacology.

Authors:  M Henning
Journal:  Acta Med Scand Suppl       Date:  1977

6.  Studies on catecholamines, renin and aldosterone following Catapresan (2-(2,6-dichlor-phenylamine)-2-imidazoline hydrochloride) in hypertensive patients.

Authors:  B Hökfelt; H Hedeland; J F Dymling
Journal:  Eur J Pharmacol       Date:  1970       Impact factor: 4.432

7.  A sensitive and specific fluorimetric method for the determination of noradrenalin and adrenalin in human plasma.

Authors:  V Renzini; C A Brunori; C Valori
Journal:  Clin Chim Acta       Date:  1970-12       Impact factor: 3.786

Review 8.  The central action of antihypertensive drugs, mediated via central alpha-receptors.

Authors:  P A van Zwieten
Journal:  J Pharm Pharmacol       Date:  1973-02       Impact factor: 3.765

9.  Purification, properties and kinetics of sheep and human renin substrates.

Authors:  S L Skinner; J R Dunn; J Mazzetti; D J Campbell; N H Fidge
Journal:  Aust J Exp Biol Med Sci       Date:  1975-02

10.  Studies on the possible contribution of a peripheral presynaptic action of clonidine and dopamine to their vascular effects under in vivo conditions.

Authors:  G Haeusler
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1976-12       Impact factor: 3.000

  10 in total
  4 in total

1.  Relationship of plasma catecholamines to blood pressure in hypertensive patients during beta-adrenoceptor blockade with and without intrinsic sympathomimetic activity.

Authors:  R Kirsten; B Heintz; D Böhmer; K Nelson; S Roth; D Welzel
Journal:  Br J Clin Pharmacol       Date:  1982       Impact factor: 4.335

Review 2.  Guanfacine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the treatment of hypertension.

Authors:  E M Sorkin; R C Heel
Journal:  Drugs       Date:  1986-04       Impact factor: 9.546

3.  Improvement of glucose tolerance in hypertensive diabetic patients treated with guanfacine one year.

Authors:  J H Hauger-Klevene; J C Scornavacchi
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

4.  Systemic and cardiac haemodynamic interactions between guanfacine and hydrallazine in hypertensive patients.

Authors:  M Velasco; A Urbina-Quintana; J Morillo; H Vizcarrondo; A Ramirez; E Hernández; O Hernández-Pieretti
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.